Bradykinin Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

Numerous clinical trials evaluate bradykinin's role in vascular regulation and associated pathologies, spanning Phase 1 to Phase 4 alongside observational protocols. These studies investigate conditions including hereditary and ACE inhibitor-induced angioedema, acute ischemic stroke, hypertension, coronary artery disease, and critical illness, examining parameters such as pharmacokinetic safety and enzymatic degradation pathways. Sponsored by academic institutions, university hospital networks, and biopharmaceutical enterprises, these trials exhibit varied statuses ranging from actively recruiting and completed to terminated or unassigned.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05834777	RECRUITING	Intradialytic Hypotension	Vanderbilt University Medical Center	2023-12-11	PHASE3
NCT07046806	RECRUITING	Hereditary Angioedema (HAE); Angioedema; Bradykinin-mediated Angioedema; C1 Inhibitor Deficiency	Institute for Asthma and Allergy	2025-03-10	PHASE1; PHASE2
NCT07290855	COMPLETED	Bradykinin-mediated Angioedema; Hereditary Angioedema (HAE)	Nang Kuang Pharmaceutical Co., Ltd.	2024-09-27	PHASE4
NCT03738878	TERMINATED	Hypertension	Vanderbilt University Medical Center	2018-11-15	PHASE4
NCT06109142	Not yet recruiting	Critically Ill Patients	Assistance Publique - Hôpitaux de Paris	2024-04-01	--
NCT06210698	Not yet recruiting	Angioedema\|Angioedemas Hereditary\|Urticaria\|Mastocytosis\|ACE Inhibitor-Induced Angioedema\|C1 Inhibitor Deficiency\|Systemic Mastocytoses\|Indolent Systemic Mastocytosis	Foundation For Rare Disease Research\|Institute for Asthma & Allergy\|Virant Diagnostics Inc.\|MedBio Reference Laboratories Inc.	2024-01-15	--
NCT06380699	Completed	Acute Ischemic Stroke	Changzhou Qianhong Bio-pharma Co. Ltd.	2023-03-16	Phase 1
NCT05304091	Unknown status	Bradykinin-mediated Angioedema	University Hospital Lille	2022-08	--
NCT04763577	Recruiting	Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor	University Hospital Grenoble\|University Hospital Paris\|University Hospital Rouen	2021-10-27	--
NCT05010876	COMPLETED	Covid19	GCS Ramsay Santé pour l'Enseignement et la Recherche	2021-02-04	PHASE2
NCT01595516	COMPLETED	Prehypertension; Hypertension	University of Colorado, Boulder	2012-02	PHASE4
NCT01574248	TERMINATED	ACE Inhibitor-associated Angioedema	Vanderbilt University Medical Center	2011-08	PHASE4
NCT02189122	COMPLETED	Healthy	Vanderbilt University	2014-07
NCT01413542	COMPLETED	Hypertension; Diabetes Type 2	Vanderbilt University	2011-11
NCT01036659	UNKNOWN	Angioedema	Bernstein, Jonathan A., M.D.	2010-05	PHASE2
NCT00166166	TERMINATED	Hyperlipidemia	Emory University	2002-07	PHASE2
NCT00223704	COMPLETED	Cardiopulmonary Bypass; Inflammation; Fibrinolysis; Surgery	Vanderbilt University	2006-05	PHASE2; PHASE3
NCT00517582	TERMINATED	Angioneurotic Edema	Vanderbilt University	2007-09	PHASE1
NCT00780481	TERMINATED	Obesity	Vanderbilt University	2007-01
NCT00780377	WITHDRAWN	Heart Transplantation	Vanderbilt University	2008-10
NCT00780637	WITHDRAWN	Heart Transplantation	Vanderbilt University	2008-10
NCT00868855	TERMINATED	Coronary Artery Disease	Vanderbilt University	2003-12	PHASE1
NCT00965393	COMPLETED	Ischaemic Heart Diseases	University of Edinburgh	2009-08
NCT00965120	COMPLETED	Ischaemic Heart Diseases	University of Edinburgh	2009-08
NCT00685945	COMPLETED	Obesity	Vanderbilt University	2007-12
NCT00176345	UNKNOWN	Coronary Artery Disease	University of Leipzig	2001-01	PHASE2
NCT00004575	COMPLETED	Healthy	National Heart, Lung, and Blood Institute (NHLBI)	2000-02	PHASE1
NCT00160888	UNKNOWN	Healthy	Heidelberg University	1999-11	PHASE1
NCT00083356	COMPLETED	Tooth, Impacted	National Institute of Nursing Research (NINR)	2004-05	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-15)

Check the Bradykinin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Bradykinin selectively binds to and activates endothelial B2 receptors, triggering a signaling cascade that stimulates the downstream release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor. This biochemical mediator release induces vascular smooth muscle relaxation and endothelial vasodilation, providing direct physiological relevance to clinical conditions such as hypertension, coronary artery disease, and bradykinin-mediated angioedema.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).